Aquestive Therapeutics, Inc. AQST Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $121.17M+69.4% | $71.55M+200% | $23.87M-12.5% | $27.27M-2.7% | ||
| $6.17M+2.1% | $6.04M-10.7% | $6.77M+17.1% | $5.78M+43.1% | ||
| $149.27M+69.2% | $88.22M+115% | $40.97M+2.7% | $39.89M-15.6% | ||
| $3.89M+2.5% | $3.8M-9.1% | $4.18M+2.3% | $4.09M-19.2% | ||
| $160.43M+58.2% | $101.42M+76.6% | $57.42M+0.6% | $57.07M-7.9% | ||
| $29.86M+190% | $10.29M+15.2% | $8.93M-10.3% | $9.95M+19.6% | ||
| $1.09M+4.2% | $1.05M-32.4% | $1.55M+2.5% | $1.51M+97.8% | ||
| $9.54M— | $0— | —— | —— | ||
| $47.61M+152% | $18.87M+3.0% | $18.31M-53.7% | $39.53M+80.0% | ||
| $45M0.0% | $45M+63.6% | $27.51M-17.8% | $33.45M— | ||
| $194.09M+20.1% | $161.58M-1.4% | $163.91M-6.7% | $175.62M+21.9% | ||
| 250M0.0% | 250M0.0% | 250M+454,445% | 55K+34.1% | ||
| -$447M-23.1% | -$363.21M-13.8% | -$319.08M-2.5% | -$311.21M-21.2% | ||
| -$33.66M+44.0% | -$60.16M+43.5% | -$106.49M+10.2% | -$118.55M-44.3% | ||
| $160.43M+58.2% | $101.42M+76.6% | $57.42M+0.6% | $57.07M-7.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aquestive Therapeutics, Inc.'s total assets?
- Aquestive Therapeutics, Inc. (AQST) holds $141.1M in total assets, up 38.0% year over year.
- How much debt does Aquestive Therapeutics, Inc. have?
- Aquestive Therapeutics, Inc. carries $64.4M in total debt against -$34.1M of shareholders' equity, a debt-to-equity ratio of -1.89.
- How much cash does Aquestive Therapeutics, Inc. have?
- Aquestive Therapeutics, Inc. holds $110.7M in cash and equivalents.
- Can Aquestive Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.10 — current assets exceed current liabilities.
- Where does Aquestive Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
